Bristol Myers Squibb (BMY) has seen a recent upswing in its stock price, but it still lags behind the overall market. Here are some key facts to consider about the company....
Recently, the European Commission (EC) has given its approval to Breyanzi, a novel treatment developed by Bristol-Myers Squibb (BMS) for Non-Hodgkin's Lymphoma (NHL)....
Bristol-Myers Squibb Company's groundbreaking NHL treatment, Breyanzi, has received approval from the European Commission (EC) for its use in patients....
Bristol-Myers Squibb Company (BMY) has gained the attention of hedge funds as the best pharmaceutical stock to invest in....
Bristol-Myers Squibb Company (BMY) experienced a decline in their stock price on Friday. The decrease can be attributed to factors such as market volatility and investor sentiment....
Bristol-Myers Squibb Company (BMY), a leading pharmaceutical company, has recently announced positive topline results from two pivotal Phase 3 trials evaluating its drug Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials have shown promising outcomes, with the drug meeting key endpoints and demonstrating effectiveness in treating the condition. Psoriatic arthritis is a chronic ...
Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....
Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors ...
Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been a steady performer in the biopharmaceutical industry, delivering a decent return of 89% for investors over the last five years....